Macular degeneration

This study tests an oral drug called STL303 for geographic atrophy, a form of dry age-related macular degeneration that causes a blind spot in central vision. About 300 adults aged 60 and older will receive either STL303 or a placebo pill for up to 2 years. The goal is to see if …

This study tests whether a remote dietary program can help people with early to intermediate age-related macular degeneration (AMD) lower their blood sugar and increase protective nutrients called carotenoids. About 32 participants will receive coaching to improve their eating ha…

This Phase 2a trial tests SCAI-005 eye drops in 50 adults with wet age-related macular degeneration (AMD). Participants will receive either a low dose, high dose, or placebo drops three times daily. The study aims to see if the drops can reduce retinal swelling and control the di…

This early-stage trial tests a gene therapy called AGX-08 for geographic atrophy, an advanced form of age-related macular degeneration that causes vision loss. The study will involve 24 people aged 50 and older, each receiving a single injection into one eye. The main goal is to …

This study will test the drug faricimab, given as eye injections, in 50 people with wet age-related macular degeneration (nAMD). The goal is to see if it improves vision and eye health. Participants will receive 4 initial doses, then more as needed. The study is observational, me…

This study looks at whether a home monitoring app can help people with wet age-related macular degeneration (eAMD) safely extend the time between Aflibercept injections. About 80 adults already receiving this treatment will use the app and have regular eye exams over one to two y…

This study tests a non-invasive laser treatment called photobiomodulation for people with early age-related macular degeneration (AMD) who have a specific type of deposit in the eye called reticular pseudodrusen. The treatment uses low-energy light to stimulate cells and reduce i…

This early study tests whether stimulating a nerve cluster behind the cheekbone (the pterygopalatine ganglion) is safe and doable for people with geographic atrophy, a severe form of age-related macular degeneration that causes blind spots. Sixty-two adults will receive either re…

This study tests a new medicine called AIV007 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. About 35 participants will receive either AIV007 or the standard treatment Eylea. The goal is to see if AIV007 can improve vision and reduce t…

This study tests an investigational drug called OCUL101 for people with wet age-related macular degeneration (AMD), a condition that causes blurry vision and can lead to blindness. OCUL101 targets two proteins involved in the disease to reduce abnormal blood vessel growth and inf…

This phase 3 trial tests whether adding Sanhuang Jingshiming Pills (a traditional Chinese herbal medicine) to standard ranibizumab injections can reduce the number of injections needed for wet age-related macular degeneration. About 450 adults aged 50-85 with active wet AMD will …

This phase 3 trial tests whether a new drug, QL1207H, works as well as the standard treatment Eylea for wet age-related macular degeneration, a leading cause of vision loss. About 356 adults aged 50 and older with active disease will receive injections every 4 weeks for 3 doses, …

This study tests an oral medication, CU06-1004, for people with diabetic macular edema (DME), a condition that causes vision loss. About 156 participants will take either a low dose, high dose, or placebo pill daily for 24 weeks. The goal is to see if the drug improves vision and…

This early-stage trial tests whether transplanting lab-grown retinal cells (made from stem cells) into the eye is safe for people with late-stage age-related macular degeneration. Nine participants will receive the cell transplant and be monitored for side effects and any improve…

This early-stage trial tests a new drug called GB10, given as an eye injection, for people with wet age-related macular degeneration (AMD). The study will include 48 participants and aims to check safety and find the right dose. It is not yet recruiting and is too early to know i…

This study tests a new, non-invasive treatment for dry age-related macular degeneration (AMD), a common cause of vision loss in older adults. About 94 people aged 50 and older with dry AMD will use a red-light device at home twice daily for three months. Researchers will check if…

This study tests whether mirabegron, a drug used for overactive bladder, can help people with dry age-related macular degeneration (AMD). Researchers will give 312 patients aged 50-80 either mirabegron or a standard bladder drug for 12 months and check for changes in the retina. …

This phase 4 trial will test the drug faricimab (Vabysmo) in 64 people with wet age-related macular degeneration (AMD). Participants will receive eye injections every 4 weeks for 4 doses, then a treat-and-extend schedule based on disease activity. The study also measures biomarke…

This study tests a stronger dose (8 mg) of the drug aflibercept in Chinese patients with polypoidal choroidal vasculopathy (PCV), a type of wet age-related macular degeneration that can cause rapid vision loss. About 174 people who have not been treated before will receive three …

This study tests an experimental pill (EG-301) taken daily for at least 6 months in 90 people with dry age-related macular degeneration (AMD) and geographic atrophy. Participants are randomly assigned to receive either standard AREDS2 supplements alone or AREDS2 plus EG-301. The …

This study tests an experimental drug called SNP318 in 60 people with diabetic macular edema, a condition that causes vision loss due to swelling in the retina. Participants will receive either the drug or a placebo, and researchers will monitor safety, eye thickness, and vision …

This study tests faricimab, a drug injected into the eye, for people with type 3 wet age-related macular degeneration (AMD), a condition that can cause rapid vision loss. Over 76 weeks, 30 participants will receive initial monthly doses, then a personalized schedule where injecti…

This early-stage trial tests EXG202, a gene therapy given as a single injection into the eye for people with wet age-related macular degeneration (AMD). The goal is to see if it is safe and can produce a protein that blocks abnormal blood vessel growth long-term, potentially redu…

This trial tests an artificial intelligence system called QiLin that helps doctors decide when to give anti-VEGF injections for retinal diseases like wet AMD, DME, and RVO. About 200 patients who have completed initial treatment will be randomly assigned to have their doctor use …

This study will develop and test an artificial intelligence system to detect common eye diseases like glaucoma, cataracts, and diabetic retinopathy using 15,000 existing eye images from Costa Rican patients. The goal is to create a tool that works accurately for local populations…

This study tests a compact, handheld eye imaging device that takes pictures of the eye in seconds. Researchers want to see if it is easy to use, mobile, and reliable. The device will be tested on 70 people with eye complaints, and the images will be compared to official diagnoses…

This study will test a new, non-invasive eye scanner called wide field OCTA in 200 people with various eye diseases, including age-related macular degeneration, diabetic retinopathy, and dry eye. The goal is to see if this device can provide better images of blood vessels in the …

This study will test a new artificial intelligence (AI) system that reads eye scans (OCT) to diagnose common blinding eye diseases like diabetic retinopathy, glaucoma, and age-related macular degeneration. Researchers will collect 2000 eye scans from patients at Peking Union Medi…

This study tests if using a cotton-tipped applicator to hold the eyelid open during eye injections is less painful and faster than the standard metal speculum. About 120 adults with certain eye conditions will take part. The goal is to improve comfort and satisfaction without com…

This study tests whether meditation or a health education program can improve quality of life and mental health for people with irreversible age-related vision loss and their caregivers. About 150 participants will be assigned to either meditation training or health classes, both…

This early study tests whether a wearable ultrasound device can safely stimulate retinal cells and help restore vision in people with age-related macular degeneration or retinitis pigmentosa. Five participants will receive short ultrasound pulses while reporting what they see. Th…

This study tests a miniaturized smart contact lens in 32 people—some healthy, some with Stargardt's disease—to see if it is comfortable and easy to use. The lens tracks eye movements to help with vision tasks. Researchers will check for side effects and ask participants how they …

This study aims to develop new methods to help veterans with vision loss caused by age-related macular degeneration. About 20 veterans aged 50 and older with reduced vision will take part. Researchers will measure how well they recognize objects and how their brains respond befor…

This study will test a new, noninvasive camera called XyCAM CRE that measures blood flow in the back of the eye. Researchers will compare its images with standard eye tests in 350 adults with retinal disorders. The goal is to see if this camera can provide extra information to he…

This study tests whether a personalized care approach helps patients with chronic macular diseases (like wet age-related macular degeneration and diabetic macular edema) attend their regular eye injection appointments. Many patients skip these vital treatments, risking further vi…

This study looks at whether giving eye doctors AI-generated measurements from retinal images helps them write more accurate and complete reports. About 29 ophthalmologists and trainees will be randomly assigned to use AI tools or just the original images. A panel of senior expert…

This study aims to see if virtual reality tests can better measure how age-related macular degeneration affects daily life compared to standard eye exams. Researchers will enroll 60 participants, including healthy adults and those with the eye condition. The goal is to develop a …

This pilot study will test two new eye imaging devices (R1 and HighRes OCT) against a standard device in 97 adults with healthy eyes or eye diseases like macular degeneration and diabetic retinopathy. Researchers will compare image quality and how well key eye structures are seen…

This study aims to see if elderly patients with age-related macular degeneration (AMD) find a new web-based eye-tracking system easy and acceptable to use at home. The system is designed to help patients monitor their vision without frequent clinic visits. Thirty patients aged 55…

This study looks back at medical records of 200 people with inherited retinal diseases, like retinitis pigmentosa and Stargardt disease. Researchers will analyze vision tests and eye scans to see how these diseases progress and how genetics affect symptoms. The goal is to find be…

This study will look at 225 adults with diabetic retinopathy to find out how many also develop an epiretinal membrane — a thin, scar-like layer on the retina that can blur vision. Researchers will use eye scans to detect the membrane and check for related factors like age, diabet…

This study looks at whether shifting text to a different part of the eye can help people with central vision loss read faster and more accurately. Researchers will test 100 participants with conditions like macular degeneration using various reading tasks. The goal is to find bet…

This study will look at 30 people with macular dystrophy to see how different eye tests—like OCT scans, mfERG, and standard vision tests—relate to each other. The goal is to better understand how these tests can track vision changes. No treatment is being tested; this is purely a…